Hooshmand Sheshbaradaran - BetterLife Pharma Chief Officer
| BETRF Stock | USD 0.08 0.01 9.59% |
Insider
Hooshmand Sheshbaradaran is Chief Officer of BetterLife Pharma
| Age | 55 |
| Phone | 778 997 1928 |
| Web | https://www.abetterlifepharma.com |
BetterLife Pharma Management Efficiency
The company has return on total asset (ROA) of (4.0469) % which means that it has lost $4.0469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (44.1654) %, meaning that it generated substantial loss on money invested by shareholders. BetterLife Pharma's management efficiency ratios could be used to measure how well BetterLife Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
| Moutih Rafei | Defence Therapeutics | 41 | |
| Sebastien Plouffe | Defence Therapeutics | 51 | |
| Carrie Cesarone | Defence Therapeutics | 58 | |
| Simon Beaudoin | Defence Therapeutics | 39 | |
| Oren Hershkovitz | Enlivex Therapeutics | 47 | |
| Pr MD | Enlivex Therapeutics | 68 | |
| Shachar CPA | Enlivex Therapeutics | 47 | |
| Sigal Arad | Enlivex Therapeutics | N/A | |
Management Performance
| Return On Equity | -44.17 | |||
| Return On Asset | -4.05 |
BetterLife Pharma Leadership Team
Elected by the shareholders, the BetterLife Pharma's board of directors comprises two types of representatives: BetterLife Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BetterLife. The board's role is to monitor BetterLife Pharma's management team and ensure that shareholders' interests are well served. BetterLife Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BetterLife Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Calandra, Head Regulatory | ||
| Ahmad Doroudian, CEO Founder | ||
| Abdi Ghaffari, Head Toxicology | ||
| Scott Rudge, Head CMC | ||
| Hooshmand Sheshbaradaran, Chief Officer |
BetterLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is BetterLife Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -44.17 | |||
| Return On Asset | -4.05 | |||
| Current Valuation | 12.42 M | |||
| Shares Outstanding | 90.1 M | |||
| Shares Owned By Insiders | 8.41 % | |||
| Price To Book | 13.65 X | |||
| Gross Profit | (22.81 K) | |||
| EBITDA | (11.92 M) | |||
| Net Income | (12.16 M) | |||
| Cash And Equivalents | 14.41 K |
Currently Active Assets on Macroaxis
Other Information on Investing in BetterLife OTC Stock
BetterLife Pharma financial ratios help investors to determine whether BetterLife OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BetterLife with respect to the benefits of owning BetterLife Pharma security.